Skip to content

Comparison of efficacy and safety of topical 5% potassium hydroxide solution and topical 0.1% retinoid lotion in the treatment of plane wart

Comparison of efficacy and safety of topical 5% potassium hydroxide solution and topical 0.1% retinoid lotion in the treatment of plane wart

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201201038516N2
Enrollment
72
Registered
2012-03-10
Start date
2009-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

plane wart. Viral infections characterized by skin and mucous membrane lesions

Interventions

Intervention 1: Topical 5% potassium hydroxide solution was applied on the lesions using cotton swap by patients or their parents, and then patients were evaluated regarding efficacy and safety of th
Treatment - Drugs
Topical 5% potassium hydroxide solution was applied on the lesions using cotton swap by patients or their parents, and then patients were evaluated regarding efficacy and safety of the drugs 2, 4, 6
In the other group topical 0.1 % retinoid lotion was applied on the wart lesions by the patient or their parents and the patients were evaluated regarding the efficacy and safety 2, 4, 6 weeks after

Sponsors

The institute of research and technology of Ahvaz jundishapur University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criterion: presence of at least three lesion Exclusion criteria: 1-Pregnancy 2-Lactation 3-Patients that have received treatment in the recent four weeks 4-Secondary infection 5-Involvement of the genital area

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Improvement. Timepoint: 2 weeks, 4 weeks, 6 weeks after initiation of the treatment and 2 weeks after the end of the treatment. Method of measurement: Based on the count of lesions.

Secondary

MeasureTime frame
Adverse drug reaction. Timepoint: 2 weeks, 4 weeks, 6 weeks after the initiation of the treatment and 2 weeks after the end of the treatment. Method of measurement: Based on occurrence of various adverse reaction.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mahroo Tajalli

Ahvaz Jundishapur University of Medical Science

mahru.tajalli@yahoo.comtajalli.m@ajums.ac.ir+98 61 1222 2114

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026